← CORCEPT THERAPEUTICS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | $8.1m |
$129.1m
+1486.27%
|
$75.4m
-41.60%
|
$94.2m
+24.89%
|
$106.0m
+12.56%
|
$112.5m
+6.13%
|
$101.4m
-9.86%
|
$106.1m
+4.66%
|
$141.2m
+33.04%
|
$99.7m
-29.43%
|
— | |
| Net Income (Loss) Available to Common Stockholders, Basic | $8.1m |
$129.1m
+1486.27%
|
$75.4m
-41.60%
|
$94.2m
+24.89%
|
$106.0m
+12.56%
|
$112.5m
+6.13%
|
$101.3m
-9.98%
|
$105.5m
+4.15%
|
$139.7m
+32.45%
|
$98.2m
-29.74%
|
— | |
| Depreciation, Depletion and Amortization | $87k | $106k | $236k | $703k | $525k | $1.1m | $782k | $577k | $795k | $1.1m | $2.4m | |
| Amortization of Debt Issuance Costs | $21k | $14k | $0 | $0 | — | — | — | — | — | — | — | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $465k | — | — | — | |
| Deferred Income Tax Expense (Benefit) | — | ($76.7m) | $14.1m | $16.9m | $14.1m | $4.3m | ($33.9m) | ($29.5m) | ($40.2m) | ($37.5m) | ($16.3m) | |
| Share-based Payment Arrangement, Noncash Expense | $7.1m | $13.4m | $23.7m | $29.3m | $33.5m | $42.9m | $42.4m | $48.9m | $61.4m | $84.5m | $96.1m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | $6.1m | $1.1m | $22.8m | $21.7m | $9.1m | $22.3m | $72.9m | — | |
| Share-based Payment Arrangement, Expense | $7.1m | $13.4m | — | — | — | — | — | — | — | — | $96.1m | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | $23.8m | $29.4m | $33.8m | $43.2m | $42.7m | $49.1m | $61.7m | $85.0m | $96.1m | |
| Nonoperating Income (Expense) | — | — | — | — | — | — | — | $17.3m | $24.5m | $21.7m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $3.6m | $5.4m | $2.3m | $2.3m | $6.3m | $1.4m | $3.4m | $10.1m | $12.9m | $5.8m | ($12.4m) | |
| Increase (Decrease) in Inventories | $682k | $2.3m | $7.8m | $1.0m | $3.5m | ($3.4m) | ($1.2m) | ($1.3m) | ($305k) | $7.5m | ($11.0m) | |
| Increase (Decrease) in Accounts Payable | $965k | $6.3m | ($389k) | ($735k) | $3.2m | ($3.6m) | $4.8m | $5.8m | ($2.2m) | $25.1m | ($9.0m) | |
| Net Cash Provided by (Used in) Operating Activities | $18.4m |
$60.9m
+231.33%
|
$115.7m
+89.82%
|
$136.1m
+17.68%
|
$152.0m
+11.65%
|
$167.9m
+10.48%
|
$120.3m
-28.33%
|
$127.0m
+5.58%
|
$198.1m
+55.91%
|
$142.0m
-28.31%
|
$109.7m
-22.74%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $194k | $419k | $298k | $1.1m | $1.2m | $469k | $413k | $139k | $2.2m | $211k | ($2.8m) | |
| Marketable Securities, Unrealized Gain (Loss) | — | ($75k) | $5k | — | — | — | — | — | — | — | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | $0 | $29.9m | $142.7m | $182.3m | $302.1m | $398.9m | $241.2m | $419.8m | $412.9m | $389.6m | — | |
| Net Cash Provided by (Used in) Investing Activities | ($194k) | ($73.5m) | ($90.8m) | ($117.8m) | ($119.3m) | $136.1m | ($114.3m) | $90.9m | ($177.6m) | $69.8m | ($21.9m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | $14.8m | $15.1m | $0 | $0 | — | — | — | — | — | — | — | |
| Payments for Repurchase of Common Stock | $0 | $0 | $23.7m | $31.0m | $9.9m | $296.0m | $0 | $145.4m | $15.7m | $172.9m | — | |
| Net Cash Provided by (Used in) Financing Activities | ($7.1m) |
($8.0m)
-12.08%
|
($14.3m)
-80.25%
|
($28.6m)
-99.83%
|
$12.2m
+142.64%
|
($302.6m)
-2577.41%
|
($17.3m)
+94.29%
|
($148.7m)
-760.47%
|
($28.3m)
+80.94%
|
($220.4m)
-677.33%
|
($78.9m)
+64.19%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | $44.9m | $1.4m | ($11.3m) | $69.2m | ($7.9m) | ($7.2m) | $112.6m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $76.2m | $77.6m | $66.3m | $135.6m | $127.7m | $120.5m | $112.6m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | — | $358k | ($228k) | $1.4m | ($602k) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $7.7m | $7.2m | — | — | — | — | — | — | — | $15.9m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, Net | $40k | $377k | $1.4m | $6.7m | $10.9m | $9.1m | $39.7m | $47.6m | $60.3m | $13.0m | — | |
| Additional Financial Items | ||||||||||||
| Accretion Expense | $1.9m | $456k | $0 | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $0 | ($76.3m) | $16.7m | $22.5m | $25.6m | $12.5m | $14.8m | $18.4m | $20.3m | ($33.2m) | — | |
| Operating Lease, Expense | — | — | — | $1.5m | $1.9m | $2.1m | $2.3m | $2.4m | — | — | — |